Karyopharm Therapeutics Inc. (KPTI)
Nasdaq · Healthcare · Biotechnology
$0.6705−16.42%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $15.2M
- 52-week range
- $0.6264 – $10.99
- 52-week change
- −86.98%
- EPS (trailing)
- −$14.33
- Next earnings
- Nov 3, 2026
Fiscal year to Dec 2025
- Revenue
- $146M (+0.57%)
- Net income
- −$196M
- Operating margin
- −62.1%
- Diluted EPS
- −$17.93
- Free cash flow
- −$75.4M
From the company’s annual report on SEC EDGAR.
About Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors.
Headquarters: Newton, United States · 228 employees · karyopharm.com